A major exchange-traded fund provider is going deep on two popular plays: megacap tech and weight loss drug stocks. In health care, Roundhill Investments is getting ready to launch a fund that focuses on the companies behind GLP-1 drugs. Dave Mazza, the firm’s chief strategy officer, expects to have more information on the fund’s debut